The overactivation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson’s disease, according to Johns Hopkins scientists. The finding of this mechanism could lead to important new targets for drugs already known to inhibit it, thus controlling symptoms of the disorder, which affects about 1 million older Americans.
Results of the new study were published Sept. 7 in the Proceedings of the National Academy of Sciences (PNAS) Online Early Edition.
